These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Application of sandostatin in malignant bowel obstruction].
    Author: Li J, Jing ML, Shen L.
    Journal: Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep; 10(5):479-81. PubMed ID: 17851794.
    Abstract:
    OBJECTIVE: To investigate the effects of sandostatin in the treatment of malignant bowel obstruction(MBO). METHODS: The data of 51 patients with MBO from Aug. 1996 to June. 2004 were analyzed retrospectively. All the patients were divided into two groups: routine treatment group (n=19) and sandostatin combined with routine treatment group (n=32). Symptoms, gastrointestinal secretions, nasogastric tube(NGT) removing and effects of sandostatin on different obstructive location were observed. RESULTS: The symptom improvement in sandostatin group was 20/32 (63.1%) which was significantly higher than 4/19 (21.1%) in routine treatment group (P< 0.01). The average G-I secretion was (398 +/- 152) ml and (834 +/- 306) ml in sandostatin and traditional group respectively and the difference was significant (P< 0.05). No severe side and toxic effects were found during therapy. CONCLUSION: Sandostatin can effectively relieve clinical symptoms and improve life quality in the bowel obstruction cases with advanced cancers.
    [Abstract] [Full Text] [Related] [New Search]